Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GC, I did not think that $700k cash actually left the company to go to the Doc. Rather, the affiliate that collects the license fees does not intend to pay those fees to the company. So the receivable from affiliate got reclassed into a receivable from the Doc...and the company will soon declare it to be uncollectable. Is that correct?
From the text: "On February 14, 2024, the Company’s CEO borrowed $700,000 from the Company.", the "loan", assuming he ever pays it back, would be for his personal use. With the over-the-top bonus clause, <$5M contract, brought to company by him, would "pay" him roughly same amount, including taxes impact. Thus, infuriatingly and typically, that looks like another indicator of no real deal near fruition, if there ever were any, near fruition, in the first place.
How about a shareholder meeting to rescind his self-dealing contracts and vote that MFer out!
Then you'd think they'd move that $700k to a line for "inventory" or AP. But a third-party loan given most likely to himself is not going to sit well with investors without explanation. And most of the time the explanations they send out are absolute BS from the company. 100K+ units to Egypt, Middle East, Caribbean, India were discussed in the past. Now, nothing from them. Always excuses or just total silence. This stinks like horse sh*t and is the last straw for most shareholders IMO. The talk about SEC complaints is growing daily and 100% warranted if this turns out to be one big criminal fraud org they are possibly running. The silence from the IR guy and the company the past few months is not helping their case either.
Your option may be possible. However, I look at it as an either/or. Either there needs to be inventory purchased, which temporarily shows up on the Balance Sheet, until shipment and delivery, or an Accounts Payable that accounts for product order being produced for drop shipment. In the recent hyped, 100000+ units to multiple countries,"on schedule" for March shipments, if they had been real, seems to require one or the other on the company books, whereas no manufacturer is going to produce that (or probably any) quantity of product, without signed, legal commitments, from this company.
Thanks for the recalibration. I had allowed myself to adopt jaded expectations, through track record of multiple otcm CEOs, over the years, and what has passed as so called "business practices". That, along with not desiring a potential, ultimate legal outcome, at this time, due to the likely injurious nature to shareholders, led to my opinion. However, thanks for the reminder that neither of those impact actual, legal responsibilities of CEO.
Borderline?
It is 100% fraudulent if proven to be true, which seems more likely now as each day passes.
The stock seems to be trading more on technicals now and looks headed to .0055 - .005. Typically there's a bounce. But with no PRs in months, No tweets in months, and the CEO taking out $700K with zero explanation is not looking great. No one seems able to get in touch with the IR guy either. Not good. This guy gets paid with millions in shares and won't even reply to anyone. What's the point of having an IR if they don't communicate with shareholders. This whole thing starting to stink like total sh*t now.
If they actually did start shipping products in March as stated, they would have PR'd that by now. 99.9% it never happened and now they'll just post some new bullsh*t excuses or just not say a word. If not, this will just slide back to the .001 range and maybe to 000s.
If anyone ever does get a hold of IR, please share the BS excuses on here. If they keep ignoring shareholders and best interests of shareholders and are just self-dealing and siphoning money out of the company, then theres going to be much bigger problems for them.
Regarding no inventory/ no payables; I wonder if VDRM will ever actually carry inventory? I suppose there could be an arrangement with a manufacturer who sells direct with an appropriate percentage back to the company. No inventory is very concerning though; I think I'm just trying to sugar coat it.
Agreed, Doc actions are clearly self-dealing. He is acting in his own best interest instead of the best interest of the company and the shareholders. It's also a huge conflict of interest and I agree with GC ...highly unethical. Other thoughts come to mind as well, gross negligent use of company assets and borderline fraudulent.
I do agree with you partially. The part you didn’t include is that this is a business and it is shareholders money, he must declare it and there should be limits to CEO to do such. It is the 2nd loan asked, for what? Can the company afford it? What if we did inherit a gambler on this CEO!!! There should be a procedure, this CEO didn’t follow or explained nobody none.
Despite of the ethical part, you know it is wrong what he is doing: The Devil is within the details
Incorrect since his Fiduciary Duty to shareholders is to declare prior why and at what terms I/e interest rate payable to the company!!!
Ooohh, thats why you don't share. Got it. Thanks for clearing that up.
CEO borrowed the funds from the company personally, as deemed credit worthy by himself, basically. Thus, it is more likely falls under ethical concern than legal one, due to his position, in my opinion.
He borrowed 7oo thou without saying what is for isn't that stealing and I think he could be held liable maybe jail? What's your thoughts?
The share structure was confirmed as unchanged yesterday. The remaining toxic debt holders do not have the ridiculously-favorable exchange rates of those previously exercised. The share price is being driven by facts of the situation, pure and simple.
Further, the latest, much hyped, game-changing, "on schedule" shipments start of 100K+ units to multiple overseas countries on March did not happen, and has not been mentioned since January 31st X post. Until proven wrong, it looks like just another in the line of much-hyped, never-achieved, never-heard-of-again, game-changing contracts from the past.
Thus, the falling stock price is due to state of things: trickle of organic sales, stalling in licensing revenue increase, two months beyond "on-schedule" shipment state, no inventory on Balance Sheet or Accounts Payable for large production drop shipments, no recent forward-looking forecast from CEO (reasonable or not), and drag of self-enrichment activities of CEO at shareholders’ expense, with effectively no performance justifying it. Currently, sadly and infuriatingly, there is nothing on screen to cause enthusiasm/share price appreciation (or even status quo).
Still wishful thinking, due to the actual product, that CEO will turn over new leaf and earn credibility, while becoming reliable, company-performance-driven, and successful for speculators/investors.
Do your FOUR followers(in seven years) feel the same?
No "real" posts? I don't even know what that means...
And, this is why I do not share...
But DumbBalls talks to rich all the time. He's got the inside scoop on everything. Everything is great.
You have never had a real or accurate post on this board and most here realize that. As far as "Better watch yourself little man".....I just wet myself with laughter.
Ur kidding, right? Why would anyone share here? "Diamond hands" and that sophistication, right! You got it all!
I'll talk to him again today!
If it goes lower it wont be under 0.005. It happened last time. Good opportunity to average down. Otiko and the toxic lenders are diluting this badly
the floor: 0.0055 . Take advantage of the average down
Yeah but a poster spoke with the company for 25 minutes and he's fine with his investment!! Thanks poster, that's very helpful information for the Board.
It’s soooo messed up that the doc just fleeced VDRM of all of its 700K potential working capital. Next there will be a company share sell off or toxic debt to pay for “inventory” production. Sooooo BS doc. Hey doc … how about concentrate your efforts on making Vitastem viable and get multiple millions times richer than robbing the company and shareholders for a measly 700K. Hey Doc … you have VDRM financial infrastructure set up to GREATLY benefit yourself … doesn’t it make sense to follow through now ??? It’s due time for you to become a MULTI millionaire and to throw us shareholders some of the crumbs … PLEASE
Not really; money receivedable , states at 5.000 $$ monthly.
i guess on the plus side he actually sold some cream to be able to give himself a $700k loan.🤣
It’s not the first time he is in this situation. He’ll come back with a FDA Viagra or Nupelo approval tech and that will get him back on the road
How can you say that with a straight face?? I think the Doc has run out of BS to sling. IMHO all credibility he might have is completely shot. What can he possibly say anymore that anyone will believe?
Where is the floor? I think 0.0055 . Take advantage of the average down
Better watch yourself, little man! My real post vs your made up one!
BTW, you wouldn't go to the trouble and if you did, you wouldn't know what to ask!
And you thought I was making this up:
sunrise73
Re: DeerBalls post# 73089
Friday, May 10, 2024 4:59:55 AM
Post#
73091
I had a 30-minute phone call with the Doc yesterday. He is well. Thanks everyone for their investments in his company but sends apologies to all for being such a scumbag. Big things are coming though. He is buying another vacation property, so he also thanks you all for that. I'll keep everyone updated when we have our next conversation.
I haven't talked to him since.
Toxic lender. Nothing else.
Now, let’s follow smart money in here. Has someone researched: Greentree Financial Group?
By Chris Cottone!!! Why is the interest of this lender in VDRM? Why risking so much into this company? What do they know/see in it that we don’t? Very interesting
Like I said before, he is a man of narrowed vision and he has been running the company like a small grocery store. It seems he got other personal priorities, maybe he sent the some to real estate at our expense. He might be expanding his portfolio, FREE, because since it is a loan, it is exempt from tax. Very lucrative if he did such. He is the Nigerian Vampire. He is bleeding us slowly but OTCM is all about that. We will be fine
Dr. O doesn’t make any sense at all. He had a viable product that if he would just market it would be rich beyond measure because of his self appointed bonus plan and stock holdings, but chooses to bleed it dry with a personal loan and share sales instead. The product is fantastic and highly needed. Use the money that the company made to produce more product and actually close a BIG deal. SMH
All depends if he can fend off any SEC complaints that might get filed since I can’t see people being too happy with the BS that the Dr has done here treating this stock like a Madoff Ponzi Scheme where only him, the IR guy and Jack Brewer from the Brewer Group seem to be making money…
What is everyone’s short and long term price targets?
I think this dwindles to the .0055s, maybe a touch lower. But I also think it could go to .0125 or so, Dr. will pump this again, it’s just a matter of *when.
Hopefully not too many of you are stuck right here…
GLTA
Regarding $1.2M payment:
Regarding shipment overseas:
There is no inventory directly shown on Balance Sheet, and Accounts Payable dropped from $17.6K to $11.7K, so it would seem unlikely that large quantity of product was produced and is ready for shipment by a 3rd party as drop shipment, and thus, one must question whether this version of significant overseas sales is just like the line of previously hyped game-changers, never to be heard from again.
As stated in previous posts, the revenue numbers have not aligned with reported state licensing agreements in place, since end of 2022. The revenue numbers only indicate 10 agreements in place since beginning of 2022. IR is ignoring email inquiries regarding this (not atypical).
From 10/24/23 PR, regarding Nupelo
The "loan", assuming he ever pays it back, would be for his personal use. With the over-the-top bonus clause, <$5M contract, brought to company by him, would have "paid" him the roughly same amount, including taxes. Thus, infuriatingly and typically, that looks like another indicator of no deal near fruition, if there ever were any, near fruition, in the first place.
As always, for all investors and speculators, it would be nice to be proved wrong, with actual contracts cash revenue, corroborated in official financial reports.
$.0074 Don't like VDRM, the Dr, IR, want to whine? Just selling is easier and less stressful... OH, YEAH, FORGOT THE RULE: IF UR DOWN, NO MATTER WHAT, YOU DON'T SELL.... Hilarious!
Oh right......another newbie..SMFH.....
There are A LOT of questions that still need to be answered!
Where is the $1.2 million payment received? Why was it not included in recent Q1 filings. More BS from otiko?
$VDRM Update: The company has received licensing payments totaling $1.2M and will be updated into our financials accordingly. More updates to follow.
— ViaDerma (@viaderma) February 1, 2024
$VDRM Update: We received very positive feedback and have successfully completed the stability requirements for the Vitastem Ultra bacitracin formula. The company is on track to begin shipping @vitastem overseas in March.
— ViaDerma (@viaderma) January 31, 2024
Hahahahahahaha 😂 it is funny to see some in here losing the patience over these drops . Soo many speculation, incredible the human being. Guys relax, it is not the first time the Doc dilute us at these levels AND lower. Relax, we will be back up in a few weeks… The way this 1Q was made leads to understand ViaDerma got a bigger agenda going On
Wow, the pps is getting ugly. Lows keep getting lower. Why would the Doc build in a graduated bonus structure based on revenue milestones along with a 100,000,000 share award if he didn't want the company to succeed? I still am hard pressed to believe that this has all been a ruse just to fleece the shareholders. On the flip side, ruse or not, the Doc gets a big fat "F" for failure to produce. In the six years or more that I have been here, he has not accomplished one thing, not one. In any normal business, he would have been uncerimoneoulsy fired long ago and escorted from the building.
People lose faith but next thing boom off to the races as we have seen before
I thought my last buy at 83 was golden, oh well. It still will be but hold great number of shares. Cookie jar empty of crazy money.
Wow this is a buyers dream easy double
even a broken clock is right twice a day. i'm gambling the slopster is right this time. my buy order is in.
Followers
|
619
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
74600
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |